Is Nidan Laborator. overvalued or undervalued?

As of 16 September 2025, the valuation grade for Nidan Laborator. has moved from very attractive to attractive. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 13.20, an EV to EBITDA of 6.97, and a Price to Book Value of 0.38, which indicate a favorable valuation compared to its peers.
In comparison to its industry, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 93.63, and Apollo Hospitals at 71.78. Despite the recent stock performance showing a decline of 44.53% over the past year versus a slight increase in the Sensex, the current valuation suggests that Nidan Laborator. may present a buying opportunity for investors looking for undervalued stocks in the hospital sector.